Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

209 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Serial Multimodality Imaging and 2-Year Clinical Outcomes of the Novel DESolve Novolimus-Eluting Bioresorbable Coronary Scaffold System for the Treatment of Single De Novo Coronary Lesions.
Abizaid A, Costa RA, Schofer J, Ormiston J, Maeng M, Witzenbichler B, Botelho RV, Costa JR Jr, Chamié D, Abizaid AS, Castro JP, Morrison L, Toyloy S, Bhat V, Yan J, Verheye S. Abizaid A, et al. Among authors: verheye s. JACC Cardiovasc Interv. 2016 Mar 28;9(6):565-74. doi: 10.1016/j.jcin.2015.12.004. JACC Cardiovasc Interv. 2016. PMID: 27013155 Free article. Clinical Trial.
The percutaneous assessment of regional and acute coronary hot unstable plaques by thermographic evaluation (PARACHUTE) study: a prospective reproducibility and prognostic clinical study using thermography to predict future ischemic cardiac events.
Verheye S, Van Langenhove G, van Es GA, Serruys P. Verheye S, et al. Int J Cardiovasc Intervent. 2004;6(2):69-75. doi: 10.1080/14628840410030397. Int J Cardiovasc Intervent. 2004. PMID: 15385205 Clinical Trial.
The effect of variable dose and release kinetics on neointimal hyperplasia using a novel paclitaxel-eluting stent platform: the Paclitaxel In-Stent Controlled Elution Study (PISCES).
Serruys PW, Sianos G, Abizaid A, Aoki J, den Heijer P, Bonnier H, Smits P, McClean D, Verheye S, Belardi J, Condado J, Pieper M, Gambone L, Bressers M, Symons J, Sousa E, Litvack F. Serruys PW, et al. Among authors: verheye s. J Am Coll Cardiol. 2005 Jul 19;46(2):253-60. doi: 10.1016/j.jacc.2005.03.069. J Am Coll Cardiol. 2005. PMID: 16022951 Free article. Clinical Trial.
Analysis of bifurcation lesions treated with novel drug-eluting dedicated bifurcation stent system: intravascular ultrasound results of the AXXESS PLUS trial.
Miyazawa A, Ako J, Hassan A, Hasegawa T, Abizaid A, Verheye S, McClean D, Neumann FJ, Grube E, Honda Y, Fitzgerald PJ. Miyazawa A, et al. Among authors: verheye s. Catheter Cardiovasc Interv. 2007 Dec 1;70(7):952-7. doi: 10.1002/ccd.21269. Catheter Cardiovasc Interv. 2007. PMID: 18044777 Clinical Trial.
A novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease: primary results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II study.
Krucoff MW, Kereiakes DJ, Petersen JL, Mehran R, Hasselblad V, Lansky AJ, Fitzgerald PJ, Garg J, Turco MA, Simonton CA 3rd, Verheye S, Dubois CL, Gammon R, Batchelor WB, O'Shaughnessy CD, Hermiller JB Jr, Schofer J, Buchbinder M, Wijns W; COSTAR II Investigators Group. Krucoff MW, et al. Among authors: verheye s. J Am Coll Cardiol. 2008 Apr 22;51(16):1543-52. doi: 10.1016/j.jacc.2008.01.020. J Am Coll Cardiol. 2008. PMID: 18420096 Free article. Clinical Trial.
209 results